Home > Publications database > Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. > print

001     141915
005     20240229105135.0
024 7 _ |a 10.1182/bloodadvances.2018023200
|2 doi
024 7 _ |a pmid:30327369
|2 pmid
024 7 _ |a pmc:PMC6199662
|2 pmc
024 7 _ |a 2473-9529
|2 ISSN
024 7 _ |a 2473-9537
|2 ISSN
024 7 _ |a 2476-9537
|2 ISSN
024 7 _ |a altmetric:49852818
|2 altmetric
037 _ _ |a DKFZ-2018-02172
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Bochtler, Tilmann
|0 P:(DE-He78)c741dc7f974390ad4310349f29aac40b
|b 0
|e First author
|u dkfz
245 _ _ |a Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.
260 _ _ |a Washington, DC
|c 2018
|b American Society of Hematology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680677018_11715
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Analysis of intraclonal heterogeneity has yielded insights into the clonal evolution of hematologic malignancies. We compared the clonal and subclonal compositions of the underlying plasma cell dyscrasia in 544 systemic light chain amyloidosis (PC-AL) patients with 519 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or symptomatic MM; ie, PC-non-AL patients). Using interphase fluorescence in situ hybridization, subclones were stringently defined as clone size below two thirds of the largest clone and an absolute difference of ≥30%. Subclones were found less frequently in the PC-AL group, at 199 (36.6%) of 544 as compared with 267 (51.4%) of 519 in the PC-non-AL group (P < .001), and were not associated with the stage of plasma cell dyscrasia in either entity. In both groups, translocation t(11;14), other immunoglobulin heavy chain translocations, and hyperdiploidy were typically found as main clones, whereas gain of 1q21 and deletions of 8p21, 13q14, and 17p13 were frequently found as subclones. There were no shifts in the subclone/main clone ratio depending on the MGUS, SMM, or MM stage of plasma cell dyscrasia. In multivariate analysis, t(11;14) was associated with lower rates of subclone formation and hyperdiploidy with higher rates. PC-AL itself lost statistical significance, demonstrating that the lower subclone frequency in AL is a reflection of its exceptionally high t(11;14) frequency. In summary, the subclone patterns in PC-AL and PC-non-AL are closely related, implying that subclone formation depends on the main cytogenetic categories and is independent of disease entity and stage.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Merz, Maximilian
|b 1
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 2
|u dkfz
700 1 _ |a Granzow, Martin
|b 3
700 1 _ |a Hoffmann, Korbinian
|b 4
700 1 _ |a Krämer, Alwin
|0 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
|b 5
|u dkfz
700 1 _ |a Raab, Marc-Steffen
|0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
|b 6
|u dkfz
700 1 _ |a Hillengass, Jens
|0 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
|b 7
|u dkfz
700 1 _ |a Seckinger, Anja
|b 8
700 1 _ |a Kimmich, Christoph
|b 9
700 1 _ |a Dittrich, Tobias
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Müller-Tidow, Carsten
|b 11
700 1 _ |a Hose, Dirk
|b 12
700 1 _ |a Goldschmidt, Hartmut
|0 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
|b 13
|u dkfz
700 1 _ |a Hegenbart, Ute
|b 14
700 1 _ |a Jauch, Anna
|b 15
700 1 _ |a Schönland, Stefan O
|b 16
773 _ _ |a 10.1182/bloodadvances.2018023200
|g Vol. 2, no. 20, p. 2607 - 2618
|0 PERI:(DE-600)2876449-3
|n 20
|p 2607 - 2618
|t Blood advances
|v 2
|y 2018
|x 2473-9537
909 C O |p VDB
|o oai:inrepo02.dkfz.de:141915
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c741dc7f974390ad4310349f29aac40b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Translational cancer research
|x 0
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
920 1 _ |0 I:(DE-He78)G330-20160331
|k G330
|l KKE Molekulare Hämatologie/Onkologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G330-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21